STAQ Pharma Supports an Innovative Intranasal Spray for COVID-19
STAQ Pharma is working with the nonprofit scientific research organization IAVI to provide support services for the production of an innovative intranasal spray targeting COVID-19. This multi-partner project aims to produce a miniprotein anti-viral blocker delivered via an intranasal device. STAQ Pharma's expertise in aseptic processing and experience with similar devices make them a key player in this project.